1
|
Sasamoto K, Hirayama S, Kon M, Seino U, Ueno T, Nagao Y, Hirayama A, Isshiki M, Idei M, Yano K, Miida T. Changes in apolipoprotein E-containing high-density lipoprotein (HDL) have little impact on HDL-cholesterol measurements using homogeneous assays in normolipidemic and dyslipidemic subjects. Clin Chim Acta 2017; 470:56-63. [PMID: 28442245 DOI: 10.1016/j.cca.2017.04.018] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2017] [Revised: 04/15/2017] [Accepted: 04/20/2017] [Indexed: 11/19/2022]
Abstract
BACKGROUND High-density lipoprotein-cholesterol (HDL-C) is generally measured using several homogeneous assays. We aimed to clarify whether apolipoprotein E-containing HDL (apoE-HDL) subfractions are altered during storage, and if so, whether such changes affect the HDL-C concentration measured using homogeneous assays. METHODS We stored serum from normolipidemic (n=32) and dyslipidemic (n=17) subjects at 4°C for up to 7days. ApoE-HDL subfractions were analyzed using native 2-dimensional gel (native 2D-gel) electrophoresis. HDL-C concentrations were determined using 2 precipitation and 4homogeneous assays. RESULTS Native 2D-gel electrophoresis revealed variously sized apoE-HDL subfractions. After 4h incubation at 37°C, subfractions of smaller particles were converted into larger particles by lecithin:cholesterol acyltransferase (LCAT) activity. After 7days storage at 4°C, the smaller subfractions were decreased in the normolipidemic group, accompanying increases in larger subfractions, whereas changes in the respective subfractions varied among individuals in the dyslipidemic group. HDL-C concentrations were significantly lower after storage at 4°C in all assays, except that using Sekisui Medical's reagent. Therefore, changes in HDL-C concentration and apoE-HDL subfractions were independent of each other. CONCLUSION ApoE-HDL subfractions change during storage, but these changes are not linked to those in HDL-C concentration measured using homogeneous assays.
Collapse
Affiliation(s)
- Kenta Sasamoto
- Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Hongo 2-1-1, Tokyo 113-8421, Japan
| | - Satoshi Hirayama
- Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Hongo 2-1-1, Tokyo 113-8421, Japan.
| | - Mika Kon
- Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Hongo 2-1-1, Tokyo 113-8421, Japan
| | - Utako Seino
- Niigata Prefectural Institute of Environmental Radiation Monitoring, Niigata Branch, Sowa 314-1, Niigata 950-2144, Japan
| | - Tsuyoshi Ueno
- Clinical laboratory, Juntendo Tokyo Koto Geriatric Medical Center, Shinsuna 3-3-20, Tokyo 136-0075, Japan
| | - Yuki Nagao
- Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Hongo 2-1-1, Tokyo 113-8421, Japan
| | - Akiko Hirayama
- Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Hongo 2-1-1, Tokyo 113-8421, Japan
| | - Miwa Isshiki
- Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Hongo 2-1-1, Tokyo 113-8421, Japan
| | - Mayumi Idei
- Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Hongo 2-1-1, Tokyo 113-8421, Japan
| | - Kouji Yano
- Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Hongo 2-1-1, Tokyo 113-8421, Japan
| | - Takashi Miida
- Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Hongo 2-1-1, Tokyo 113-8421, Japan
| |
Collapse
|
2
|
Newly developed apolipoprotein A-I mimetic peptide promotes macrophage reverse cholesterol transport in vivo. Int J Cardiol 2015; 192:82-8. [DOI: 10.1016/j.ijcard.2015.05.012] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/06/2014] [Revised: 03/26/2015] [Accepted: 05/06/2015] [Indexed: 01/26/2023]
|
3
|
Hafiane A, Genest J. High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk. BBA CLINICAL 2015; 3:175-88. [PMID: 26674734 PMCID: PMC4661556 DOI: 10.1016/j.bbacli.2015.01.005] [Citation(s) in RCA: 116] [Impact Index Per Article: 12.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/06/2014] [Revised: 01/16/2015] [Accepted: 01/26/2015] [Indexed: 12/31/2022]
Abstract
Plasma high density lipoprotein cholesterol (HDL) comprises a heterogeneous family of lipoprotein species, differing in surface charge, size and lipid and protein compositions. While HDL cholesterol (C) mass is a strong, graded and coherent biomarker of cardiovascular risk, genetic and clinical trial data suggest that the simple measurement of HDL-C may not be causal in preventing atherosclerosis nor reflect HDL functionality. Indeed, the measurement of HDL-C may be a biomarker of cardiovascular health. To assess the issue of HDL function as a potential therapeutic target, robust and simple analytical methods are required. The complex pleiotropic effects of HDL make the development of a single measurement challenging. Development of laboratory assays that accurately HDL function must be developed validated and brought to high-throughput for clinical purposes. This review discusses the limitations of current laboratory technologies for methods that separate and quantify HDL and potential application to predict CVD, with an emphasis on emergent approaches as potential biomarkers in clinical practice.
Collapse
Key Words
- 2D-PAGGE, two dimensional polyacrylamide gradient gel electrophoresis
- ApoA-I, apolipoprotein A-I
- Apolipoprotein A-I
- Atherosclerosis
- Biomarkers of cardiovascular risk
- CHD, coronary heart disease
- CVD, cardiovascular disease
- Cellular cholesterol efflux
- Coronary artery disease
- HDL, high density lipoprotein
- HPLC, High Performance Liquid Chromatography
- High density lipoproteins
- LCAT, lecithin–cholesterol acyltransferase
- LDL, low density lipoprotein
- MALDI, matrix-assisted laser desorption/ionization
- MOP, myeloperoxidase
- MS/MS, tandem-mass spectrometry
- ND-PAGGE, non-denaturant polyacrylamide gradient gel electrophoresis
- NMR, nuclear magnetic resonance
- PEG, polyethylene glycol
- PON1, paraoxonase 1
- SELDI, surface enhanced laser desorption/ionization
- TOF, time-of-flight
- UTC, ultracentrifugation
- Vascular endothelial function
Collapse
Affiliation(s)
- Anouar Hafiane
- McGill University Health Center, Royal Victoria Hospital, 687 Avenue des Pins West, Montreal, QC H3A 1A1, Canada
| | - Jacques Genest
- McGill University Health Center, Royal Victoria Hospital, 687 Avenue des Pins West, Montreal, QC H3A 1A1, Canada
| |
Collapse
|
4
|
Shimizu T, Miura SI, Tanigawa H, Kuwano T, Zhang B, Uehara Y, Saku K. Rosuvastatin Activates ATP-Binding Cassette Transporter A1–Dependent Efflux Ex Vivo and Promotes Reverse Cholesterol Transport in Macrophage Cells in Mice Fed a High-Fat Diet. Arterioscler Thromb Vasc Biol 2014; 34:2246-53. [DOI: 10.1161/atvbaha.114.303715] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Tomohiko Shimizu
- From the Departments of Cardiology (T.S., S.M., H.T., T.K., Y.U., K.S.), Molecular Cardiovascular Therapeutics (S.M., Y.U., K.S.), Biochemistry (B.Z.), and Advanced Therapeutics for Cardiovascular Disease (H.T., K.S.), Fukuoka University School of Medicine, Fukuoka, Japan
| | - Shin-ichiro Miura
- From the Departments of Cardiology (T.S., S.M., H.T., T.K., Y.U., K.S.), Molecular Cardiovascular Therapeutics (S.M., Y.U., K.S.), Biochemistry (B.Z.), and Advanced Therapeutics for Cardiovascular Disease (H.T., K.S.), Fukuoka University School of Medicine, Fukuoka, Japan
| | - Hiroyuki Tanigawa
- From the Departments of Cardiology (T.S., S.M., H.T., T.K., Y.U., K.S.), Molecular Cardiovascular Therapeutics (S.M., Y.U., K.S.), Biochemistry (B.Z.), and Advanced Therapeutics for Cardiovascular Disease (H.T., K.S.), Fukuoka University School of Medicine, Fukuoka, Japan
| | - Takashi Kuwano
- From the Departments of Cardiology (T.S., S.M., H.T., T.K., Y.U., K.S.), Molecular Cardiovascular Therapeutics (S.M., Y.U., K.S.), Biochemistry (B.Z.), and Advanced Therapeutics for Cardiovascular Disease (H.T., K.S.), Fukuoka University School of Medicine, Fukuoka, Japan
| | - Bo Zhang
- From the Departments of Cardiology (T.S., S.M., H.T., T.K., Y.U., K.S.), Molecular Cardiovascular Therapeutics (S.M., Y.U., K.S.), Biochemistry (B.Z.), and Advanced Therapeutics for Cardiovascular Disease (H.T., K.S.), Fukuoka University School of Medicine, Fukuoka, Japan
| | - Yoshinari Uehara
- From the Departments of Cardiology (T.S., S.M., H.T., T.K., Y.U., K.S.), Molecular Cardiovascular Therapeutics (S.M., Y.U., K.S.), Biochemistry (B.Z.), and Advanced Therapeutics for Cardiovascular Disease (H.T., K.S.), Fukuoka University School of Medicine, Fukuoka, Japan
| | - Keijiro Saku
- From the Departments of Cardiology (T.S., S.M., H.T., T.K., Y.U., K.S.), Molecular Cardiovascular Therapeutics (S.M., Y.U., K.S.), Biochemistry (B.Z.), and Advanced Therapeutics for Cardiovascular Disease (H.T., K.S.), Fukuoka University School of Medicine, Fukuoka, Japan
| |
Collapse
|
5
|
Validation of homogeneous assays for HDL-cholesterol using fresh samples from healthy and diseased subjects. Atherosclerosis 2014; 233:253-9. [PMID: 24529153 DOI: 10.1016/j.atherosclerosis.2013.12.033] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/29/2013] [Revised: 12/09/2013] [Accepted: 12/13/2013] [Indexed: 11/23/2022]
Abstract
BACKGROUND High-density lipoprotein-cholesterol (HDL-C) is a negative risk factor for cardiovascular events. Although several homogeneous HDL-C assays are available, their accuracy has not been validated, particularly in subjects with disease. We aimed to clarify whether HDL-C concentrations measured by homogeneous assays [HDL-C (H)] agree with those determined by the reference measurement procedures [HDL-C (RMP)] using ultracentrifugation and precipitation with heparin-manganese reagent in fresh clinical samples. METHODS HDL-C concentrations in samples from 48 healthy subjects and 119 subjects with disease were determined using 12 homogeneous assays and RMPs. RESULTS All reagents showed excellent intra- and inter-assay CVs (<2.23%) for two pooled sera. Furthermore, the mean bias was within ± 1.0% in nine reagents using samples from healthy subjects and in eight reagents using samples from subjects with disease. In a single HDL-C (H) determination, the total error requirement of the National Cholesterol Education Program (95% of results < 13%) was fulfilled in nine reagents using samples from healthy subjects and six reagents in those from subjects with disease. Error component analysis revealed that only one reagent exceeded ± 10% total error in samples from healthy subjects, whereas four reagents exceeded this error in samples from subjects with disease. Correlations between HDL-C (H) and HDL-C (RMP) revealed that the slopes were within 1.00 ± 0.06 in six reagents in healthy subjects, and eight reagents in subjects with disease. CONCLUSIONS Except for three reagents, HDL-C (H) agrees well with HDL-C (RMP) in subjects with common disease, but not in those with extremely low HDL-C or abnormal HDL composition.
Collapse
|
6
|
Imaizumi S, Kiya Y, Miura SI, Zhang B, Matsuo Y, Uehara Y, Rye KA, Saku K. Pharmacological Intervention Using Reconstituted High-Density Lipoprotein Changes in the Lipid Profile in Spontaneously Hypersensitive Rats. Clin Exp Hypertens 2010; 32:202-8. [DOI: 10.3109/10641960903265196] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
7
|
Characterization of in vitro modified human high-density lipoprotein particles and phospholipids by capillary zone electrophoresis and LC ESI-MS. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877:3495-505. [DOI: 10.1016/j.jchromb.2009.08.022] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2009] [Revised: 08/07/2009] [Accepted: 08/12/2009] [Indexed: 11/22/2022]
|
8
|
Capillary isotachophoresis study of lipoprotein network sensitive to apolipoprotein E phenotype. 1. ApoE distribution between lipoproteins. Mol Cell Biochem 2009; 325:41-51. [DOI: 10.1007/s11010-008-0018-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2008] [Accepted: 12/30/2008] [Indexed: 10/21/2022]
|
9
|
|
10
|
Imaizumi S, Miura SI, Nakamura K, Kiya Y, Uehara Y, Zhang B, Matsuo Y, Urata H, Ideishi M, Rye KA, Sata M, Saku K. Antiarrhythmogenic effect of reconstituted high-density lipoprotein against ischemia/reperfusion in rats. J Am Coll Cardiol 2008; 51:1604-12. [PMID: 18420105 DOI: 10.1016/j.jacc.2007.12.040] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/14/2007] [Revised: 12/04/2007] [Accepted: 12/10/2007] [Indexed: 11/19/2022]
Abstract
OBJECTIVES This study analyzed the antiarrhythmogenic effect of reconstituted high-density lipoprotein (rHDL) against ischemia/reperfusion in vivo. BACKGROUND Recent studies have suggested that a reduction in the plasma HDL level may contribute to cardiac sudden death. Although there are currently only a few therapeutic strategies for increasing HDL, an exciting new therapeutic option, rHDL, has recently been developed to prevent coronary artery disease. METHODS To analyze the suppression of reperfusion arrhythmia by rHDL (apolipoprotein A-I with 1-palmitoyl-2-oleoyl-phosphatidyl-choline), 92 male Wistar rats were divided into 10 groups: rats that had been pre-treated with or without rHDL, apolipoprotein A-I, or 1-palmitoyl-2-oleoyl-phosphatidyl-choline in the presence or absence of inhibitors of Akt protein kinase, nitric oxide (NO), or extracellular-signal-regulated kinase (ERK) administered intravenously before left coronary artery occlusion. We also used human coronary artery endothelial cells and adenosine triphosphate-binding cassette transporter (ABC) A1-, ABCG1-, or scavenger receptor class B, type I-transfected ldlA7 cells systems. RESULTS The duration of ventricular tachycardia or ventricular fibrillation after reperfusion in rHDL-pre-treated rats was much shorter than that in untreated rats. Apolipoprotein A-I or 1-palmitoyl-2-oleoyl-phosphatidyl-choline alone had no effect. The effect of rHDL was blocked by inhibitors of Akt, NO, and ERK. Plasma NO concentration in the rHDL group was significantly higher. In addition, rHDL activated phospho(p)-Akt, p-ERK, and p-endothelial NO synthesis in endothelial cells. The rHDL activated p-ERK in ABCA1- or ABCG1-transfected but not scavenger receptor class B, type I-transfected ldlA7 cells. CONCLUSIONS The rHDL-induced NO production, probably mediated by ABCA1 or ABCG1 through an Akt/ERK/NO pathway in endothelial cells, may suppress reperfusion-induced arrhythmias. The HDL-based therapy may hold the promise of reducing the incidence of such arrhythmias after ischemia/reperfusion.
Collapse
Affiliation(s)
- Satoshi Imaizumi
- Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Uehara Y, Tsuboi Y, Zhang B, Miura SI, Baba Y, Higuchi MA, Yamada T, Rye KA, Saku K. POPC/apoA-I discs as a potent lipoprotein modulator in Tangier disease. Atherosclerosis 2007; 197:283-9. [PMID: 17560579 DOI: 10.1016/j.atherosclerosis.2007.04.025] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/01/2006] [Revised: 04/16/2007] [Accepted: 04/25/2007] [Indexed: 01/13/2023]
Abstract
Tangier disease (TD) is a rare familial disorder with mutations in the ATP-binding cassette transporter A1 (ABCA1) gene. It results in extremely low levels of HDL cholesterol. Since TD is a genetic disorder, a therapeutic approach to TD has not been established. We report a typical case of TD with a homozygous novel point mutation in the ABCA1 gene by using genomic DNA sequencing. Primary monocyte-derived macrophages of blood from a patient with TD and normolipidemic subjects were compared for cholesterol efflux. The macrophages from the TD patient showed no apoA-I-mediated cholesterol efflux. In contrast, POPC/apoA-I discs were able to take up cholesterol from macrophages from both the TD and normolipidemic subject. Capillary isotachophoresis (cITP), which separates lipoprotein into subfractions according to electrophoretic mobility, was used to characterize plasma lipoprotein subfractions. Both slow-migrating HDL (sHDL) and slow-migrating LDL (sLDL; unmodified LDL) subfractions were extremely low in the patient with TD. After incubation of plasma from the TD patient with POPC/apoA-I discs, sHDL and sLDL subfractions rapidly appeared. In conclusion, POPC/apoA-I discs not only have beneficial effects on cholesterol efflux, but also have potential as a lipoprotein modulator in patients with TD.
Collapse
Affiliation(s)
- Yoshinari Uehara
- Department of Neurology and Healthcare, Fukuoka University Hospital, 7-45-1 Nanakuma, Jonan-ku, 814-0180 Fukuoka, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Zhang B, Uehara Y, Hida S, Miura SI, Rainwater DL, Segawa M, Kumagai K, Rye KA, Saku K. Effects of reconstituted HDL on charge-based LDL subfractions as characterized by capillary isotachophoresis. J Lipid Res 2007; 48:1175-89. [PMID: 17327623 DOI: 10.1194/jlr.m600227-jlr200] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Modified LDL in human plasma including small, dense LDL (sdLDL) and oxidized LDL carries a more negative charge than unmodified LDL and is atherogenic. We examined the effects of apolipoprotein A-I (apoA-I)/POPC discs on charge-based LDL subfractions as determined by capillary isotachophoresis (cITP). Three normal healthy subjects and seven patients with metabolic disorders were included in the study. LDL in human plasma was separated into two major subfractions, fast- and slow-migrating LDL (fLDL and sLDL), by cITP. Normal LDL was characterized by low fLDL, and mildly oxidized LDL in vitro and mildly modified LDL in human plasma were characterized by increased fLDL. Moderately oxidized LDL in vitro and moderately modified LDL in a patient with hypertriglyceridemia and HDL deficiency were characterized by both increased fLDL and a new LDL subfraction with a faster mobility than fLDL [very-fast-migrating LDL as determined by cITP (vfLDL)]. cITP LDL subfractions with faster electrophoretic mobility (fLDL vs. sLDL, vfLDL vs. fLDL) were associated with an increased content of sdLDL. Incubation of a plasma fraction with d>1.019 g/ml (depleted of triglyceride-rich lipoproteins) in the presence of apoA-I/POPC discs at 37 degrees C greatly decreased vfLDL and fLDL but increased sLDL. Incubation of whole plasma from patients with an altered distribution of cITP LDL subfractions in the presence of apoA-I/POPC discs also greatly decreased fLDL but increased sLDL. ApoA-I/POPC discs decreased the cITP fLDL level, the free cholesterol concentration, and platelet-activating factor acetylhydrolase activity in the sdLDL subclasses (d=1.040-1.063 g/ml) and increased the size of LDL. ApoA-I/POPC discs reduced charge-modified LDL in human plasma by remodeling cITP fLDL into sLDL subfractions.
Collapse
Affiliation(s)
- Bo Zhang
- Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Miura SI, Saku K. Therapies for raising high-density lipoprotein cholesterol. Intern Med 2007; 46:339-40. [PMID: 17409593 DOI: 10.2169/internalmedicine.46.6206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|